Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture

Zhu, Kun; Zhang, J.; Zhang, C.; Zhao, Zhi; Gao, Jun; Li, X.; Xia, Xi; Xu, Xiufeng; Zhang, T.; Guan, Jianzhong

doi:10.1007/s00198-020-05637-0

Cited by 8 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, 15 studies were excluded after reading the full text for the irrelevant content or low quality. Finally, 6 RCTs ( 18 – 23 ) were included in this study.…”

Section: Resultsmentioning

confidence: 99%

“…Three RCTs ( 18 , 22 , 23 ) involving 88 patients in ZA group and 86 patients in control group reported the changes of procollagen type I N-terminal propeptide (PINP) at 6 and 12 months after THA. The pooled result demonstrated PINP was significantly decreased in ZA group compared with control group at 6 and 12 months after THA (MD = −26.16, 95% CI : −31.23 to −21.09, P < 0.00001; MD = −38.64, 95% CI : −47.51 to −29.77, P < 0.00001, Figure 9 ).…”

Section: Resultsmentioning

confidence: 99%

“…The pooled result demonstrated PINP was significantly decreased in ZA group compared with control group at 6 and 12 months after THA (MD = −26.16, 95% CI : −31.23 to −21.09, P < 0.00001; MD = −38.64, 95% CI : −47.51 to −29.77, P < 0.00001, Figure 9 ). Additionally, only three of six RCTs ( 18 , 20 , 23 ) mentioned that blood vitamin D and calcium levels were normal before administrating ZA.…”

Section: Resultsmentioning

confidence: 99%

“…Six RCTs ( 18 – 23 ) involving 155 patients in the ZA group and 152 patients in the control group recorded the HHS at 12 months after THA. The pooled results showed that the HHS was significantly increased in the ZA group compared with the control group at 12 months after THA (MD = 4.87, 95% CI : 0.64–9.1, P = 0.02, Figure 10 ).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Zoledronic Acid for Periprosthetic Bone Mineral Density Changes in Patients With Osteoporosis After Hip Arthroplasty—An Updated Meta-Analysis of Six Randomized Controlled Trials

Liu

Xu²,

Li³

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Introduction: Periprosthetic bone mineral density (BMD) loss following total hip arthroplasty (THA) may threaten the survival of the implant, especially in patients with osteoporosis. Zoledronic acid (ZA) is the representative of the third generation of bisphosphonates, which were effective in reducing bone loss in conditions associated with accelerated bone turnover. The aim of this study was to evaluate the efficacy and safety of ZA in patients with osteoporosis after THA.Methods: Randomized controlled trials (RCTs) associated with ZA and THA were searched from the MEDLINE, PubMed, EMBASE, Wanfang database, and the Web of Science (August 2021). Other methods, such as hand search and email request were also tried. The methodological quality was assessed by the Risk of Bias (RoB) 2.0. Relevant data were abstracted from the included RCTs and authors were contacted when necessary.Results: In this study, six RCTs involving a total of 307 patients were finally included and analyzed. The pooled data demonstrated that significantly less periprosthetic BMD loss in Gruen zone seven had occurred in the ZA-treated patients than in the control patients at 3 months (mean difference [MD] = 4.03%; 95% CI: 0.29–7.76%; P = 0.03), 6 months (MD = 7.04%; 95% CI: 2.12–11.96%; P = 0.005), and 12 months (MD = 7.12%; 95% CI: 0.33–13.92%; P = 0.04). The Harris Hip Score (HHS) was also significantly increased in ZA group at 6 and 12 months after operation (P = 0.03 and P = 0.02, respectively). Influenza-like symptom was found related to the usage of ZA [relative risk (RR) = 7.03, P < 0.0001].Conclusion: A meta-analysis of six RCTs suggested that ZA was beneficial in maintaining the periprosthetic BMD in patients with osteoporosis at 6 and 12 months after THA. In addition, the HHS was significantly improved in patients treated with ZA. However, the short length of follow-up of the available studies resulted in the lack of analyses regarding the survival of implants including the rate of aseptic loosing, periprosthetic fracture, and revision. It still needs to be determined in research with longer follow-up period.Clinical Trial Registration:Researchregistry.com, identifier: reviewregistry1087.

show abstract

“…Then, 15 studies were excluded after reading the full text for the irrelevant content or low quality. Finally, 6 RCTs ( 18 – 23 ) were included in this study.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Zoledronic Acid for Periprosthetic Bone Mineral Density Changes in Patients With Osteoporosis After Hip Arthroplasty—An Updated Meta-Analysis of Six Randomized Controlled Trials

Liu

Xu²,

Li³

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Postoperative systemic administration of antiresorptive drugs is limited by various side effects and low bioavailability that consistently achieves an unsatisfactory local osseointegration effect (Frank et al, 2021). Poor osseointegration after joint replacement leads to serious complications, including prosthesis loosening or displacement and periprosthetic fracture (Zhu et al, 2021). Therefore, to ameliorate the pathological environment in the osteoporotic interface, an effective treatment that can promote osseointegration at the prosthetic interface after joint replacement is urgently required.…”

Section: Introductionmentioning

confidence: 99%

DataSheet1.PDF

View full text Add to dashboard Cite

The Healing and therapeutic effects of perioperative bisphosphonate use in patients with fragility fractures: meta-analysis of 19 clinical trials

Zeng,

Yang,

Wang

et al. 2024

Osteoporos Int

View full text Add to dashboard Cite

Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture

Cited by 8 publications

References 20 publications

Zoledronic Acid for Periprosthetic Bone Mineral Density Changes in Patients With Osteoporosis After Hip Arthroplasty—An Updated Meta-Analysis of Six Randomized Controlled Trials

Zoledronic Acid for Periprosthetic Bone Mineral Density Changes in Patients With Osteoporosis After Hip Arthroplasty—An Updated Meta-Analysis of Six Randomized Controlled Trials

DataSheet1.PDF

The Healing and therapeutic effects of perioperative bisphosphonate use in patients with fragility fractures: meta-analysis of 19 clinical trials

Contact Info

Product

Resources

About